Free Trial

Needham & Company LLC's Rating of Nurix Therapeutics on 10/13/2026

On October 13, 2026, Needham & Company LLC updated its outlook on Nurix Therapeutics (NASDAQ:NRIX) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Needham & Company LLC

DateCompanyAction
10/13/2026
SentinelOne, Inc. stock logo
S
SentinelOne
Boost Price Target
10/13/2026
Better Home & Finance Holding Company stock logo
BETR
Better Home & Finance
Lower Price Target
10/13/2026
Equifax, Inc. stock logo
EFX
Equifax
Lower Price Target
10/13/2026
Fair Isaac Corporation stock logo
FICO
Fair Isaac
Lower Price Target
10/13/2026
TransUnion stock logo
TRU
TransUnion
Lower Price Target
10/13/2026
MongoDB, Inc. stock logo
MDB
MongoDB
Reiterated Rating
More Ratings From Needham & Company LLC